PARSIPPANY, N.J. / Aug 20, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET.
Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
Last Trade: | US$166.96 |
Daily Change: | 0.33 0.20 |
Daily Volume: | 1,943,491 |
Market Cap: | US$75.330B |
November 04, 2024 September 26, 2024 August 06, 2024 May 02, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load